TACTIC: a multicentre, open-label, single-arm phase II trial of panitumumab, cisplatin, and gemcitabine in biliary tract cancer

被引：0
|
作者：
D. Ferraro
D. Goldstein
R. L. O’Connell
J. R. Zalcberg
K. M. Sjoquist
N. C. Tebbutt
P. Grimison
S. McLachlan
L. L. Lipton
P. Vasey
V. J. Gebski
C. Aiken
M. Cronk
S. Ng
C. S. Karapetis
J. Shannon
机构：
[1] University of Sydney,National Health and Medical Research Council Clinical Trials Centre
[2] University of New South Wales,Prince of Wales Clinical School
[3] Monash University,Department of Epidemiology and Preventive Medicine
[4] Austin Health,Haematology and Oncology Clinics of Australasia
[5] Chris O’Brien Lifehouse,Department of Medical Oncology
[6] St Vincents Hospital,Department of Pathology
[7] University of Melbourne,undefined
[8] Western Health,undefined
[9] Wesley Medical Centre,undefined
[10] Nambour General Hospital,undefined
[11] Flinders University,undefined
[12] Nepean Cancer Care Centre,undefined
[13] University of Melbourne,undefined
[14] Sir Charles Gairdner Hospital,undefined
来源：
Cancer Chemotherapy and Pharmacology | 2016年 / 78卷
关键词：
Biliary tract cancer; KRAS; Panitumumab; Chemotherapy; Phase II trial; Cancer antigen 19.9;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
下载
收藏
页码：361 / 367
页数：6
相关论文
共 50 条
  • [1] TACTIC: a multicentre, open-label, single-arm phase II trial of panitumumab, cisplatin, and gemcitabine in biliary tract cancer
    Ferraro, D.
    Goldstein, D.
    O'Connell, R. L.
    Zalcberg, J. R.
    Sjoquist, K. M.
    Tebbutt, N. C.
    Grimison, P.
    McLachlan, S.
    Lipton, L. L.
    Vasey, P.
    Gebski, V. J.
    Aiken, C.
    Cronk, M.
    Ng, S.
    Karapetis, C. S.
    Shannon, J.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2016, 78 (02) : 361 - 367
  • [2] Camrelizumab plus gemcitabine and oxaliplatin (GEMOX) in patients with advanced biliary tract cancer: a single-arm, open-label, phase II trial
    Chen, Xiaofeng
    Wu, Xiaofeng
    Wu, Hao
    Gu, Yanhong
    Shao, Yang
    Shao, Qianwen
    Zhu, Feipeng
    Li, Xiao
    Qian, Xiaofeng
    Hu, Jun
    Zhao, Fengjiao
    Mao, Weidong
    Sun, Jing
    Wang, Jian
    Han, Gaohua
    Li, Changxian
    Xia, Yongxiang
    Seesaha, Poshita Kumari
    Zhu, Dongqin
    Li, Huajun
    Zhang, Junling
    Wang, Guoqiang
    Wang, Xuehao
    Li, Xiangcheng
    Shu, Yongqian
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 (02)
  • [3] Durvalumab plus gemcitabine/cisplatin/nab-paclitaxel in resectable biliary tract cancer: A phase II, single-arm, open-label study (DurGAP)
    Li, Rentao
    Liu, Yang
    Liu, Yayue
    Fu, Linlin
    Qi, Qi
    Zhang, Xihao
    Cui, Yunlong
    Lu, Wei
    Li, Huikai
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [4] A single-arm phase II trial of gemcitabine, oxaliplatin, and panitumumab in KRAS wild-type advanced biliary tract cancer
    Noel, Marcus Smith
    Allen, Jill N.
    Abrams, Thomas Adam
    Yurgelun, Matthew
    Faris, Jason Edward
    Goyal, Lipika
    Clark, Jeffrey W.
    Blaszkowsky, Lawrence Scott
    Murphy, Janet E.
    Zheng, Hui
    Khorana, Alok A.
    Connolly, Gregory Clayton
    Hyrien, Ollivier
    Ng, Kimmie
    Borger, Darrell R.
    Iafrate, Anthony John
    Hezel, Aram F.
    Zhu, Andrew X.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (03)
  • [5] Regorafenib-avelumab combination in patients with biliary tract cancer (REGOMUNE): a single-arm, open-label, phase II trial
    Cousin, Sophie
    Cantarel, Coralie
    Guegan, Jean-Philippe
    Mazard, Thibault
    Gomez-Roca, Carlos
    Metges, Jean-Philippe
    Bellera, Carine
    Adenis, Antoine
    Korakis, Iphigenie
    Poureau, Pierre-Guillaume
    Bourcier, Kevin
    Toulmonde, Maud
    Kind, Michele
    Rey, Christophe
    Auzanneau, Celine
    Bessede, Alban
    Soubeyran, Isabelle
    Italiano, Antoine
    EUROPEAN JOURNAL OF CANCER, 2022, 162 : 161 - 169
  • [6] A single-arm, multicenter, open-label phase 2 trial of surufatinib in patients with unresectable or metastatic biliary tract cancer
    Xu, Jianming
    Bai, Yuxian
    Sun, Huichuan
    Bai, Chunmei
    Jia, Ru
    Li, Yi
    Zhang, Wenjie
    Liu, Lei
    Huang, Cheng
    Guan, Mei
    Zhou, Jinghong
    Su, Weiguo
    CANCER, 2021, 127 (21) : 3975 - 3984
  • [7] Cadonilimab in combined with gemcitabine and cisplatin in advanced biliary tract cancer (BicureX): A phase II, single-arm clinical trial.
    Ma, Ji
    Wang, Tao
    Chen, Yidi
    Yang, Yi
    Qiu, Yiwen
    Shen, Shu
    Yi, Cheng
    Wang, Wentao
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [8] Apatinib plus camrelizumab in patients with advanced cervical cancer: A multicentre, open-label, single-arm, phase II trial
    Huang, X.
    Shen, J.
    Xiong, Y.
    Wang, Y.
    Cao, X.
    He, M.
    Zou, G.
    Deng, Y.
    Wang, X.
    Lan, C.
    GYNECOLOGIC ONCOLOGY, 2020, 159 : 43 - 43
  • [9] Envafolimab combined with lenvatinib and gemcitabine plus cisplatin in advanced biliary tract cancer as first-line treatment: A single-arm, open-label, phase II study (ENLIGHTEN study)
    Kuang, Ming
    Xu, Lixia
    Zhang, Mengping
    Zheng, Gaomin
    Zhang, Chuankai
    Zhang, Ying
    Su, Tianhong
    Wang, Jifei
    Wang, Fang
    Wang, Fengjie
    Chen, Huanwei
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [10] A single-arm, multicenter, open-label phase 2 trial of surufatinib in patients with unresectable or metastatic biliary tract cancer.
    Bai, Yuxian
    Xu, Jianming
    Sun, Huichuan
    Bai, Chunmei
    Jia, Ru
    Li, Yi
    Zhang, Wenjie
    Liu, Lei
    Huang, Cheng
    Guan, Mei
    Zhou, Jinghong
    Su, Weiguo
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
12345